Abbott receives CE Mark approval for fresh blood sugar monitoring system Abbott today announced that it has received CE Tag because of its new FreeStyle InsuLinx BLOOD SUGAR Monitoring System, the first blood glucose monitoring device from Abbott which includes a mealtime insulin calculator for calculating suggested insulin dosages. The new FreeStyle InsuLinx System also offers several additional user-friendly features, including a touch screen interface, automated logbook, personalization preferences and USB connection for plug-and-play reviews via the brand new FreeStyle Auto-Help data management software Read more about this drug . The FreeStyle InsuLinx System will be accessible in select countries within Europe beginning in May.
With a portfolio of leading, science-structured offerings in diagnostics, medical products, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs 69 approximately,000 people.. Abbott enhances its placement in fast-growing Latin American market Abbott has announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, a lot more than doubling its Latin American branded generics pharmaceutical presence and additional expanding Abbott’s presence in fast-growing markets. Beneath the terms of the contract, Abbott will find the holding firm that indirectly owns approximately 73 % of CFR Pharmaceuticals and will conduct a public money tender give for all of the excellent shares of CFR.